Next Article in Journal
Using Patient-Derived Xenograft (PDX) Models as a ‘Black Box’ to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial
Next Article in Special Issue
Advances in Promoting the Efficacy of Chimeric Antigen Receptor T Cells in the Treatment of Hepatocellular Carcinoma
Previous Article in Journal
The Histone Demethylase HR Suppresses Breast Cancer Development through Enhanced CELF2 Tumor Suppressor Activity
Previous Article in Special Issue
Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo
 
 
Review

Article Versions Notes

Action Date Notes Link
article pdf uploaded. 24 September 2022 13:49 CEST Version of Record https://0-www-mdpi-com.brum.beds.ac.uk/2072-6694/14/19/4651/pdf-vor
article xml file uploaded 27 September 2022 10:01 CEST Original file -
article xml uploaded. 27 September 2022 10:01 CEST Update -
article pdf uploaded. 27 September 2022 10:01 CEST Updated version of record https://0-www-mdpi-com.brum.beds.ac.uk/2072-6694/14/19/4651/pdf-vor
article html file updated 27 September 2022 10:06 CEST Original file -
article html file updated 27 September 2022 10:06 CEST Update -
article html file updated 27 September 2022 10:18 CEST Update -
article xml file uploaded 29 September 2022 16:07 CEST Update -
article xml uploaded. 29 September 2022 16:07 CEST Update https://0-www-mdpi-com.brum.beds.ac.uk/2072-6694/14/19/4651/xml
article pdf uploaded. 29 September 2022 16:07 CEST Updated version of record https://0-www-mdpi-com.brum.beds.ac.uk/2072-6694/14/19/4651/pdf
article html file updated 29 September 2022 16:08 CEST Update -
article html file updated 29 September 2022 16:09 CEST Update -
article html file updated 29 September 2022 16:11 CEST Update -
article html file updated 28 February 2023 15:10 CET Update https://0-www-mdpi-com.brum.beds.ac.uk/2072-6694/14/19/4651/html
Back to TopTop